Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives

Area of Science:

• Genetics
• Metabolic Disorders
• Bone Diseases

Background:

• X-linked hypophosphatemia (XLH) is a rare genetic metabolic disorder.
• It stems from fibroblast growth factor 23 (FGF23) dysregulation, causing reduced renal phosphate reabsorption.
• XLH presents with impaired growth, rickets, skeletal deformities in children, and osteoarthritis in adults.

Purpose of the Study:

• To review perspectives in patient care for XLH.
• To highlight the importance of multidisciplinary specialist care for rare bone diseases.
• To optimize treatment and reduce the clinical burden of XLH.

Main Methods:

• Literature review of XLH patient care.
• Analysis of multidisciplinary approaches in rare bone disease centers.
• Synthesis of current treatment strategies and outcomes.

Main Results:

• Burosumab, an FGF23 antibody, shows promising results in phase III studies for children with XLH.
• Complete phenotypic rescue is rarely achieved with current treatments.
• Multisystemic symptoms necessitate ongoing specialist care.

Conclusions:

• Multidisciplinary care coordination is essential for optimizing XLH patient management.
• Targeted therapies combined with comprehensive care can reduce disease burden.
• Expert centers for rare bone diseases play a vital role in managing XLH.